Figure 1From: Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literatureClinical charateristics of evaluated patients during six months of follow-up. Disease Activity Score in 28 Joints (DAS28) (a), Simple Disease Activity Index (SDAI) (b), Patient Global Visual Analogue Scale (PG-VAS) (c), erythrocyte sedimentation rate (ESR) (d), C-reactive protein values (CRP) (e), body weight (f), fasting plasma glucose (g) and glycosylated hemoglobin (h) concentrations in our two patients at the beginning of anakinra treatment and after three and six months of follow-up.Back to article page